- Home
- EQR vs IQV Comparison
EQR vs IQV Comparison
Compare EQR & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- IQV
- Stock Information
- Founded
- EQR 1993
- IQV 1982
- Country
- EQR United States
- IQV United States
- Employees
- EQR N/A
- IQV N/A
- Industry
- EQR Real Estate Investment Trusts
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- EQR Real Estate
- IQV Health Care
- Exchange
- EQR Nasdaq
- IQV Nasdaq
- Market Cap
- EQR 26.7B
- IQV 27.2B
- IPO Year
- EQR 1993
- IQV 2013
- Fundamental
- Price
- EQR $66.26
- IQV $164.24
- Analyst Decision
- EQR Buy
- IQV Buy
- Analyst Count
- EQR 15
- IQV 20
- Target Price
- EQR $79.00
- IQV $226.80
- AVG Volume (30 Days)
- EQR 2.0M
- IQV 2.3M
- Earning Date
- EQR 07-28-2025
- IQV 07-22-2025
- Dividend Yield
- EQR 4.14%
- IQV N/A
- EPS Growth
- EQR 8.50
- IQV 0.26
- EPS
- EQR 2.62
- IQV 7.35
- Revenue
- EQR $3,010,100,000.00
- IQV $15,497,000,000.00
- Revenue This Year
- EQR $5.13
- IQV $5.40
- Revenue Next Year
- EQR $4.28
- IQV $5.20
- P/E Ratio
- EQR $25.56
- IQV $22.36
- Revenue Growth
- EQR 3.81
- IQV 2.84
- 52 Week Low
- EQR $59.41
- IQV $134.65
- 52 Week High
- EQR $78.84
- IQV $252.88
- Technical
- Relative Strength Index (RSI)
- EQR 43.05
- IQV 66.26
- Support Level
- EQR $65.87
- IQV $155.15
- Resistance Level
- EQR $68.09
- IQV $167.32
- Average True Range (ATR)
- EQR 1.32
- IQV 4.12
- MACD
- EQR -0.14
- IQV 0.73
- Stochastic Oscillator
- EQR 38.63
- IQV 78.48
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.